Treatment options for osteogenesis imperfecta

Bibliography

• Forlino A, Cabral WA, Barnes AM, et al. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7(9):540-57
   PubMed Web of Science ®Google Scholar
• Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 2008;20(5):495-501
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403-34
   PubMed Web of Science ®Google Scholar
• Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16(2):101-16
   PubMed Web of Science ®Google Scholar
• Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007;28(3):209-21
   PubMed Web of Science ®Google Scholar
• Forlino A, Tani C, Rossi A, et al. Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics 2007;7(11):1877-91
   PubMed Web of Science ®Google Scholar
• Morello R, Bertin TK, Chen Y, et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006;127(2):291-304
   PubMed Web of Science ®Google Scholar
• Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007;39(3):359-65
   PubMed Web of Science ®Google Scholar
• van Dijk FS, Nesbitt IM, Zwikstra EH, et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 2009;85(4):521-7
   PubMed Web of Science ®Google Scholar
• Hudson DM, Eyre DR. Collagen prolyl 3-hydroxylation: a major role for a minor post-translational modification? Connect Tissue Res 2013;54(4-5):245-51
   PubMed Web of Science ®Google Scholar
• Shaheen R, Alazami AM, Alshammari MJ, et al. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J Med Genet 2012;49(10):630-5
   PubMed Web of Science ®Google Scholar
• Christiansen HE, Schwarze U, Pyott SM, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet 2010;86(3):389-98
   PubMed Web of Science ®Google Scholar
• Alanay Y, Avaygan H, Camacho N, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2010;86(4):551-9
   PubMed Web of Science ®Google Scholar
• Nagai N, Hosokawa M, Itohara S, et al. Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis. J Cell Biol 2000;150(6):1499-506
   PubMed Web of Science ®Google Scholar
• Barnes AM, Cabral WA, Weis M, et al. Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix. Hum Mutat 2012;33(11):1589-98
   PubMed Web of Science ®Google Scholar
• Puig-Hervás MT, Temtamy S, Aglan M, et al. Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome-osteogenesis imperfecta phenotypic spectrum. Hum Mutat 2012;33(10):1444-9
   PubMed Web of Science ®Google Scholar
• Martínez-Glez V, Valencia M, Caparrós-Martín JA, et al. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat 2012;33(2):343-50
   PubMed Web of Science ®Google Scholar
• Semler O, Garbes L, Keupp K, et al. A mutation in the 5’-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 2012;91(2):349-57
   PubMed Web of Science ®Google Scholar
• Becker J, Semler O, Gilissen C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011;88(3):362-71
   PubMed Web of Science ®Google Scholar
• Glorieux FH, Moffatt P. Osteogenesis imperfecta, an ever-expanding conundrum. J Bone Miner Res 2013;28(7):1519-22
   PubMed Web of Science ®Google Scholar
• Moffatt P, Gaumond MH, Salois P, et al. Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res 2008;23(9):1497-508
   PubMed Web of Science ®Google Scholar
• Becerra SP, Notario V. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer 2013;13(4):258-71
   PubMed Web of Science ®Google Scholar
• Li F, Song N, Tombran-Tink J, et al. Pigment epithelium-derived factor enhances differentiation and mineral deposition of human mesenchymal stem cells. Stem Cells 2013;31(12):2714-23
   PubMed Web of Science ®Google Scholar
• Lapunzina P, Aglan M, Temtamy S, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet 2010;87(1):110-14
   PubMed Web of Science ®Google Scholar
• Pyott SM, Tran TT, Leistritz DF, et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet 2013;92(4):590-7
   PubMed Web of Science ®Google Scholar
• Symoens S, Malfait F, D’hondt S, et al. Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans. Orphanet J Rare Dis 2013;8:154
   PubMed Web of Science ®Google Scholar
• Harrington J, Sochett E, Howard A. Update on the Evaluation and Treatment of Osteogenesis Imperfecta. Pediatr Clin North Am 2014;61(6):1243-57
   PubMed Web of Science ®Google Scholar
• Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr 2008;20(1):52-7
   PubMed Web of Science ®Google Scholar
• Janus GJ, Finidori G, Engelbert RH, et al. Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation. Eur Spine J 2000;9(6):486-91
   PubMed Web of Science ®Google Scholar
• Yilmaz G, Hwang S, Oto M, et al. Surgical treatment of scoliosis in osteogenesis imperfecta with cement-augmented pedicle screw instrumentation. J Spinal Disord Tech 2014;27(3):174-80
   PubMed Web of Science ®Google Scholar
• Krishnan H, Patel NK, Skinner JA, et al. Primary and revision total hip arthroplasty in osteogenesis imperfecta. Hip Int 2013;23(3):303-9
   PubMed Web of Science ®Google Scholar
• Sawin PD, Menezes AH. Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management. J Neurosurg 1997;86(6):950-60
   PubMed Web of Science ®Google Scholar
• Papapoulos SE. Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 2008;22(5):831-47
   PubMed Web of Science ®Google Scholar
• Rao SH, Evans KD, Oberbauer AM, et al. Bisphosphonate treatment in the oim mouse model alters bone modeling during growth. J Biomech 2008;41(16):3371-6
   PubMed Web of Science ®Google Scholar
• Evans KD, Sheppard LE, Rao SH, et al. Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta. Int J Biomed Sci 2009;5(4):345-52
   PubMedGoogle Scholar
• McCarthy EA, Raggio CL, Hossack MD, et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 2002;52(5):660-70
   PubMed Web of Science ®Google Scholar
• Camacho NP, Carroll P, Raggio CL. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. Calcif Tissue Int 2003;72(5):604-9
   PubMed Web of Science ®Google Scholar
• Misof BM, Roschger P, Baldini T, et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 2005;36(1):150-8
   PubMed Web of Science ®Google Scholar
• Camacho NP, Raggio CL, Doty SB, et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 2001;69(2):94-101
   PubMed Web of Science ®Google Scholar
• Uveges TE, Kozloff KM, Ty JM, et al. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res 2009;24(5):849-59
   PubMed Web of Science ®Google Scholar
• Sekiya H, Murakami T, Saito A, et al. Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice. J Bone Miner Metab 2009;28(4):384-94
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Malghem J, Maldague B, et al. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;16(5):360-3
   PubMed Web of Science ®Google Scholar
• Aström E, Söderhäll S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998;87(1):64-8
   PubMed Web of Science ®Google Scholar
• Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339(14):947-52
   PubMed Web of Science ®Google Scholar
• Alcausin MB, Briody J, Pacey V, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr 2013;79(6):333-40
   PubMed Web of Science ®Google Scholar
• Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85(5):1846-50
   PubMed Web of Science ®Google Scholar
• Rauch F, Travers R, Plotkin H, et al. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110(9):1293-9
   PubMed Web of Science ®Google Scholar
• Barros ER, Saraiva GL, de Oliveira TP, et al. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2012;25(5-6):485-91
   PubMed Web of Science ®Google Scholar
• Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004;363(9419):1427-31
   PubMed Web of Science ®Google Scholar
• Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 2011;96(2):355-64
   PubMed Web of Science ®Google Scholar
• Rauch F, Munns CF, Land C, et al. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 2009;24(7):1282-9
   PubMed Web of Science ®Google Scholar
• Bishop N, Adami S, Ahmed SF, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382(9902):1424-32
   PubMed Web of Science ®Google Scholar
• Shapiro JR, McCarthy EF, Rossiter K, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 2003;72(2):103-12
   PubMed Web of Science ®Google Scholar
• Shapiro JR, Thompson CB, Wu Y, et al. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 2010;87(2):120-9
   PubMed Web of Science ®Google Scholar
• Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003;18(1):126-30
   PubMed Web of Science ®Google Scholar
• Pavón de Paz I, Iglesias Bolaños P, Durán Martínez M, et al. [Effects of zoledronic acid in adults with osteogenesis imperfecta]. Endocrinol Nutr 2010;57(6):245-50
   PubMedGoogle Scholar
• Chevrel G, Schott AM, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 2006;21(2):300-6
   PubMed Web of Science ®Google Scholar
• O’Sullivan ES, van der Kamp S, Kilbane M, et al. Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort. Ir J Med Sci 2013;183(2):225-30
   PubMed Web of Science ®Google Scholar
• Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 2012;23(1):285-94
   PubMed Web of Science ®Google Scholar
• Land C, Rauch F, Munns CF, et al. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006;39(4):901-6
   PubMed Web of Science ®Google Scholar
• Nicolaou N, Agrawal Y, Padman M, et al. Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates. J Child Orthop 2013;6(1):21-7
   Google Scholar
• Alharbi M, Pinto G, Finidori G, et al. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res 2009;71(1):38-44
   PubMed Web of Science ®Google Scholar
• Munns CF, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004;19(11):1779-86
   PubMed Web of Science ®Google Scholar
• Hennedige AA, Jayasinghe J, Khajeh J, et al. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res 2013;4(4):e1
   PubMedGoogle Scholar
• Kamoun-Goldrat A, Ginisty D, Le Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008;116(3):195-8
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 2014;124(2):491-8
   PubMed Web of Science ®Google Scholar
• Holm J, Eiken P, Hyldstrup L, et al. Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide. Endocr Pract 2014;20(10):e187-90
   PubMed Web of Science ®Google Scholar
• Kawai M, Mödder UI, Khosla S, et al. Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 2011;10(2):141-56
   PubMed Web of Science ®Google Scholar
• King D, Jarjoura D, McEwen HA, et al. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta. J Bone Miner Res 2005;20(6):987-93
   PubMed Web of Science ®Google Scholar
• King D, Chase J, Havey RM, et al. Effects of growth hormone transgene expression on vertebrae in a mouse model of osteogenesis imperfecta. Spine (Phila Pa 1976) 2005;30(13):1491-5
   PubMed Web of Science ®Google Scholar
• Antoniazzi F, Bertoldo F, Mottes M, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996;129(3):432-9
   PubMed Web of Science ®Google Scholar
• Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 2003;18(2):237-43
   PubMed Web of Science ®Google Scholar
• Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 2010;6:367-81
   PubMed Web of Science ®Google Scholar
• Antoniazzi F, Monti E, Venturi G, et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol 2010;163(3):479-87
   PubMed Web of Science ®Google Scholar
• Hussar DA, Stevenson T. New drugs: denosumab, dienogest/estradiol valerate, and polidocanol. J Am Pharm Assoc (2003) 2010;50(5):658-62
   PubMed Web of Science ®Google Scholar
• Honma M, Ikebuchi Y, Kariya Y, et al. RANKL subcellular trafficking and regulatory mechanisms in osteocytes. J Bone Miner Res 2013;28(9):1936-49
   PubMed Web of Science ®Google Scholar
• Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011;17(10):1235-41
   PubMed Web of Science ®Google Scholar
• Bargman R, Huang A, Boskey AL, et al. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res 2010;51(2):123-31
   PubMed Web of Science ®Google Scholar
• Hoyer-Kuhn H, Semler O, Schoenau E. Effect of denosumab on the growing skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab 2014;99(11):3954-5
   PubMed Web of Science ®Google Scholar
• Semler O, Netzer C, Hoyer-Kuhn H, et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 2012;12(3):183-8
   PubMed Web of Science ®Google Scholar
• Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 2010;25(9):1897-904
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24(4):578-88
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, et al. Single-ose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26(1):19-26
   PubMed Web of Science ®Google Scholar
• Sinder BP, Eddy MM, Ominsky MS, et al. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 2012;28(1):73-80
   Web of Science ®Google Scholar
• Sinder BP, White LE, Salemi JD, et al. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int 2014;25(8):2097-107
   PubMed Web of Science ®Google Scholar
• Roschger A, Roschger P, Keplingter P, et al. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 2014;66:182-8
   PubMed Web of Science ®Google Scholar
• Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009;15(7):757-65
   PubMed Web of Science ®Google Scholar
• Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996;132(1-2):195-210
   PubMed Web of Science ®Google Scholar
• Grafe I, Yang T, Alexander S, et al. Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nat Med 2014;20(6):670-5
   PubMed Web of Science ®Google Scholar
• Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011;79(11):1236-43
   PubMed Web of Science ®Google Scholar
• Cabral WA, Marini JC. High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet 2004;74(4):752-60
   PubMed Web of Science ®Google Scholar
• Li F, Wang X, Niyibizi C. Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation. Stem Cells 2007;25(12):3183-93
   PubMed Web of Science ®Google Scholar
• Wang X, Li F, Niyibizi C. Progenitors systemically transplanted into neonatal mice localize to areas of active bone formation in vivo: implications of cell therapy for skeletal diseases. Stem Cells 2006;24(8):1869-78
   PubMed Web of Science ®Google Scholar
• Jones GN, Moschidou D, Abdulrazzak H, et al. Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta. Stem Cells Dev 2014;23(3):262-76
   PubMed Web of Science ®Google Scholar
• Mehrotra M, Rosol M, Ogawa M, et al. Amelioration of a mouse model of osteogenesis imperfecta with hematopoietic stem cell transplantation: microcomputed tomography studies. Exp Hematol 2010;38(7):593-602
   PubMed Web of Science ®Google Scholar
• Li F, Wang X, Niyibizi C. Bone marrow stromal cells contribute to bone formation following infusion into femoral cavities of a mouse model of osteogenesis imperfecta. Bone 2010;47(3):546-55
   PubMed Web of Science ®Google Scholar
• Pauley P, Matthews BG, Wang L, et al. Local transplantation is an effective method for cell delivery in the osteogenesis imperfecta murine model. Int Orthop 2014;38(9):1955-62
   PubMed Web of Science ®Google Scholar
• Guillot PV, Abass O, Bassett JH, et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood 2008;111(3):1717-25
   PubMed Web of Science ®Google Scholar
• Panaroni C, Gioia R, Lupi A, et al. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood 2009;114(2):459-68
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001;97(5):1227-31
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99(13):8932-7
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Götherström C, Ringdén O, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005;79(11):1607-14
   PubMed Web of Science ®Google Scholar
• Götherström C, Westgren M, Shaw SW, et al. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med 2014;3(2):255-64
   PubMed Web of Science ®Google Scholar
• Shapiro JR, Rowe DW. Genetic approach to treatment of osteogenesis imperfecta in osteogenesis imperfecta. 1st edition. Elsevier Science and Technology, Oxford, UK, 2013;12:529-45
   Google Scholar
• Khillan JS, Li SW, Prockop DJ. Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene. Proc Natl Acad Sci USA 1994;91(14):6298-302
   PubMed Web of Science ®Google Scholar
• Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest 1996;97(2):448-54
   PubMed Web of Science ®Google Scholar
• Grassi G, Forlino A, Marini JC. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res 1997;25(17):3451-8
   PubMed Web of Science ®Google Scholar
• Toudjarska I, Kilpatrick MW, Niu J, et al. Delivery of a hammerhead ribozyme specifically downregulates mutant type I collagen mRNA in a murine model of osteogenesis imperfecta. Antisense Nucleic Acid Drug Dev 2001;11(5):341-6
   PubMedGoogle Scholar
• Dawson PA, Marini JC. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res 2000;28(20):4013-20
   PubMed Web of Science ®Google Scholar
• Millington-Ward S, McMahon HP, Allen D, et al. RNAi of COL1A1 in mesenchymal progenitor cells. Eur J Hum Genet 2004;12(10):864-6
   PubMed Web of Science ®Google Scholar
• Rousseau J, Gioia R, Layrolle P, et al. Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta. Eur J Hum Genet 2013;22(5):667-74
   PubMed Web of Science ®Google Scholar
• Lindahl K, Rubin CJ, Kindmark A, et al. Allele dependent silencing of COL1A2 using small interfering RNAs. Int J Med Sci 2008;5(6):361-5
   PubMedGoogle Scholar
• Lindahl K, Kindmark A, Laxman N, et al. Allele dependent silencing of collagen type I using small interfering RNAs targeting 3’UTR Indels - a novel therapeutic approach in osteogenesis imperfecta. Int J Med Sci 2013;10(10):1333-43
   PubMed Web of Science ®Google Scholar
• Zhang G, Guo B, Wu H, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 2012;18(2):307-14
   PubMed Web of Science ®Google Scholar
• McNamara JOII, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24(8):1005-15
   PubMed Web of Science ®Google Scholar
• Niyibizi C, Smith P, Mi Z, et al. Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo. J Cell Biochem 2001;83(1):84-91
   PubMed Web of Science ®Google Scholar
• Chamberlain JR, Schwarze U, Wang PR, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004;303(5661):1198-201
   PubMed Web of Science ®Google Scholar
• Chamberlain JR, Deyle DR, Schwarze U, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther 2008;16(1):187-93
   PubMed Web of Science ®Google Scholar
• Deyle DR, Khan IF, Ren G, et al. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther 2012;20(1):204-13
   PubMed Web of Science ®Google Scholar
• Gioia R, Panaroni C, Besio R, et al. Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells 2012;30(7):1465-76
   PubMed Web of Science ®Google Scholar
• Li H, Jiang X, Delaney J, et al. Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine. Am J Pathol 2010;176(5):2405-13
   PubMed Web of Science ®Google Scholar